Journal of Diabetes Science and Technology最新文献_第5页

The Impact of Interfering Substances on Continuous Glucose Monitors: Part 2: Marketed Continuous Glucose Monitoring Designs, Labeled Interfering Substances, and Design Mitigations. 干扰物质对连续血糖监测仪的影响：第2部分：上市的CGM设计、标记的干扰物质和设计缓解

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-10-16 DOI: 10.1177/19322968251377008

Steven John Setford

{"title":"The Impact of Interfering Substances on Continuous Glucose Monitors: Part 2: Marketed Continuous Glucose Monitoring Designs, Labeled Interfering Substances, and Design Mitigations.","authors":"Steven John Setford","doi":"10.1177/19322968251377008","DOIUrl":"10.1177/19322968251377008","url":null,"abstract":"Presented is a series of narrative reviews that summarize published information regarding the effect or potential effect of interfering substances on the accuracy of continuous glucose monitoring (CGM) devices. While drawing together what is currently known regarding this topic, the future direction in this field and clinical implications posed by polypharmacy on CGM performance are considered. This second in a series of review articles introduces the glucose-sensing designs of commercially available continuous glucose monitors (CGMs) and describes those interfering substances currently or historically identified within manufacturer's labeling for a given CGM model. Where known, an overview of the mechanistic effects of labeled interfering substances on the corresponding CGM designs is also described, as are sensor design approaches introduced by leading manufacturers to reduce interference effects. The review also considers: the effect of interferents on market-leading minimally invasive CGMs; design changes made to limit the flux of interfering substances to the sensor's glucose-sensing element; and an appraisal of the minimally invasive implantable Senseonics Eversense system, which employs a unique synthetic glucose-recognition ligand coupled to optical signal generation, which correspondingly gives rise to a unique interference profile.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1684-1695"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12531190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145300899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

First in Human Feasibility Study: Automated Insulin Delivery Utilizing a Self-Adapting Algorithm in Adults With Type 1 and Type 2 Diabetes. 首次人体可行性研究：利用自适应算法对成人1型和2型糖尿病患者自动胰岛素输送。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-07-03 DOI: 10.1177/19322968251349528

Tom Wilkinson, Solita Donnelly, Claire Lever, Jonathan Williman, Renee Meier, Alisa Boucsein, Shirley Jones, Dave Ballagh, Reon van Rensburg, Rachael Sampson, Enrique Campos-Náñez, Steve Patek, Ryan Paul, Benjamin Wheeler, Martin de Bock

{"title":"First in Human Feasibility Study: Automated Insulin Delivery Utilizing a Self-Adapting Algorithm in Adults With Type 1 and Type 2 Diabetes.","authors":"Tom Wilkinson, Solita Donnelly, Claire Lever, Jonathan Williman, Renee Meier, Alisa Boucsein, Shirley Jones, Dave Ballagh, Reon van Rensburg, Rachael Sampson, Enrique Campos-Náñez, Steve Patek, Ryan Paul, Benjamin Wheeler, Martin de Bock","doi":"10.1177/19322968251349528","DOIUrl":"10.1177/19322968251349528","url":null,"abstract":"Background: This feasibility study assessed a novel self-adapting closed-loop system which does not require carbohydrate announcement, in adults with type 1 and type 2 diabetes.Methods: Single-arm study, comprising a 14-day run-in using participants' usual insulin therapy with a blinded continuous glucose monitor (CGM), followed by 12 weeks use of the novel closed-loop system. The algorithm adjusted its own parameters after 4, 6, 8, and 10 weeks of use.Results: Thirty-two participants with type 1 and 10 participants with type 2 diabetes were enrolled. Mean time in range (TIR; % CGM readings = 70-180 mg/dL) was 37.7% at baseline and 55.9% during the intervention period in type 1 diabetes; 17.6% at baseline and 51.5% during the intervention period in type 2 diabetes. Median time <70 mg/dL during the intervention period was 1.1% in type 1 and 0.0% in type 2 diabetes. Median TIR was 65% following the fourth algorithm adaptation. Median daily insulin delivered by manual bolus was 1.0 units in type 1 and 0.0 units in type 2 diabetes, consistent with no meal announcement. There were four serious adverse events: worsening retinopathy, severe hypoglycemia following a period of paused automation, and two hospitalizations unrelated to the device.Conclusions: A closed-loop algorithm that adjusts its own parameters and requires no meal announcement was feasible in a cohort of adults with type 1 and type 2 diabetes. Clinical benefits were most apparent with the fully adapted algorithm.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1557-1564"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12226515/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Impact of Interfering Substances on Continuous Glucose Monitors Part 3: A Review of Non-Labeled Substances Influencing Continuous Glucose Monitor Readings. 干扰物质对连续血糖监测仪的影响第3部分：影响连续血糖监测仪读数的非标记物质综述

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-10-18 DOI: 10.1177/19322968251377019

Steven John Setford

{"title":"The Impact of Interfering Substances on Continuous Glucose Monitors Part 3: A Review of Non-Labeled Substances Influencing Continuous Glucose Monitor Readings.","authors":"Steven John Setford","doi":"10.1177/19322968251377019","DOIUrl":"10.1177/19322968251377019","url":null,"abstract":"Presented is a series of narrative reviews that summarize published information regarding the effect or potential effect of interfering substances on the accuracy of continuous glucose monitoring (CGM) devices. While drawing together what is currently known regarding this topic, the future direction in this field and clinical implications posed by polypharmacy on CGM performance are considered. This third in a series of articles lists substances that have been found to influence readings from specific continuous glucose monitor (CGM) models. Points covered include: (1) A review of non-labeled substances that have been found, through in vivo or in vitro assessment, to influence CGM readings; (2) A consideration of substances found to influence CGM readings to an extent that warrants further investigations to determine if a clinically significant in vivo interfering effect occurs at therapeutically or nutritionally relevant levels of a substance and, as such, would require labeling by the manufacturer; and (3) the possibility of predicting if a new medication or formulation is predisposed to influencing CGM readings, based on an assessment of chemical structure or chemical classification. Evidence suggests that a more systematic approach to interference testing would be of value in determining if additional labeling is required for currently marketed CGMs. It is possible that many of the substances reported have previously been assessed by manufacturers and are within acceptance criteria such that product labeling is not required according to currently recognized definitions of interference. Nevertheless, it would be beneficial for this information to be publicly disclosed.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1696-1713"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12536010/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145318226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Count to 10, or Count Your Losses. 数到10，或者数你的损失。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2026-08-06 DOI: 10.1177/19322968261475689

Deepak Chinagi, Shruti Sheelin, Girish Kullolli, Tejaswini Vallabha

引用次数: 0

Development of an Extended Gate Field Effect Transistor Enzymatic Sensor to Monitor Glucose in Human Plasma. 一种扩展门场效应晶体管酶传感器用于监测人血浆中的葡萄糖。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-11-02 DOI: 10.1177/19322968251384979

David Probst, Jack Twiddy, Mika Hatada, Michael Daniele, Koji Sode

引用次数: 0

Prediction of Blood Glucose in Human Tissue Across Days by Non-Invasive Near-Infrared Spectroscopy. 用无创近红外光谱法预测人体组织血糖。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2026-08-17 DOI: 10.1177/19322968261475681

Austin J Gessell, Maosong Ye, Mark A Arnold, Gary W Small

{"title":"Prediction of Blood Glucose in Human Tissue Across Days by Non-Invasive Near-Infrared Spectroscopy.","authors":"Austin J Gessell, Maosong Ye, Mark A Arnold, Gary W Small","doi":"10.1177/19322968261475681","DOIUrl":"10.1177/19322968261475681","url":null,"abstract":"Background: Near-infrared spectroscopy was used to implement noninvasive glucose measurements from 8 volunteers with type I diabetes. The objective of the study was to evaluate a practical protocol for calibrating the spectroscopic measurement.Methods: Three trials were conducted for each of 8 subjects that spanned an average of 16 days. Each trial consisted of an oral glucose tolerance test (OGTT) performed over 4 to 5 hours during which spectra were collected continuously from a skin fold on the back of the hand. The spectra were submitted to a calibration procedure based on a combination of direct orthogonal signal correction and hybrid linear analysis. For each subject, the set of calibration spectra consisted of the data from trial 1 for that subject augmented with a set of spectra from the current trial that corresponded to the beginning fasting period of the OGTT. For each prediction day, this updating procedure would require a single reference glucose measurement and the collection of a corresponding set of spectra.Results: Across the 16 trials performed after the initial OGTT, values of the standard error of prediction ranged from 1.12 to 4.11 mM and averaged 2.33 mM. The mean average relative deviation between predicted and reference glucose values ranged from 0.079 to 0.45 and averaged 0.21 (21%). Error grids computed from 6710 predicted concentrations had 96.7% of the values in the A and B regions.Conclusions: These results represent a clear step forward in the development of a practical calibration protocol for the noninvasive measurement of blood glucose.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1533-1542"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13486390/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148793888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of a Continuous Glucose Monitoring-Based Insulin Titration Protocol for Inpatients With Type 2 Diabetes in Non-Intensive Care Unit Settings. 非重症监护病房2型糖尿病住院患者基于连续血糖监测的胰岛素滴定方案的评估

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-04-05 DOI: 10.1177/19322968251331628

Mikkel Thor Olsen, Ulrik Pedersen-Bjergaard, Signe Hjejle Jensen, Louise Mathorne Rasmussen, Carina Kirstine Klarskov, Birgitte Lindegaard, Jonas Askø Andersen, Hans Gottlieb, Suzanne Lunding, Katrine Bagge Hansen, Peter Lommer Kristensen

{"title":"Evaluation of a Continuous Glucose Monitoring-Based Insulin Titration Protocol for Inpatients With Type 2 Diabetes in Non-Intensive Care Unit Settings.","authors":"Mikkel Thor Olsen, Ulrik Pedersen-Bjergaard, Signe Hjejle Jensen, Louise Mathorne Rasmussen, Carina Kirstine Klarskov, Birgitte Lindegaard, Jonas Askø Andersen, Hans Gottlieb, Suzanne Lunding, Katrine Bagge Hansen, Peter Lommer Kristensen","doi":"10.1177/19322968251331628","DOIUrl":"10.1177/19322968251331628","url":null,"abstract":"Background: No widely adopted continuous glucose monitoring (CGM)-based insulin titration protocol exists, which may limit the effects of inpatient CGM on glycemic and clinical outcomes. We evaluate the acceptability and operability of the protocol proposed by Olsen et al for inpatients with type 2 diabetes in non-intensive care unit (non-ICU) settings.Method: 7 inpatient diabetes team members, responsible for daily insulin titration, decided on insulin adjustments for 353 days. The members had the option to follow the CGM-based insulin protocol or override it for basal, prandial, and correctional insulin, separately, in 84 inpatients monitored by CGM. Questionnaires were used to evaluate the protocol's operability by the teams.Results: Of 456 basal insulin titration decisions, 439 (96.3%) adhered to the protocol. For prandial insulin, adherence rates were 83.9% (125/149) for breakfast, 87.2% (130/149) for lunch, and 92.6% (138/149) for dinner (p=0.163). All correctional insulin titrations adhered to the protocol. All team members expressed a preference for having a protocol for CGM-based insulin titration and rated the protocol's usability on a 1 to 10 scale, with mean scores (SD) of 8.7 (0.9) for basal insulin, 8.3 (1.4) for prandial insulin, and 7.4 (1.9) for correctional insulin.Conclusions: The CGM-based insulin titration protocol by Olsen et al has been successfully implemented for titrating basal, prandial, and correctional insulin in inpatients with type 2 diabetes in non-ICU settings. It was highly accepted by inpatient diabetes teams and provides a framework for effective CGM implementation in these settings.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1604-1612"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11977621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Glucose Oxidoreductases for Glucose Monitoring: A Bird's Eye View of Glucose-Sensing Enzymes II. 葡萄糖氧化还原酶用于葡萄糖监测：葡萄糖感应酶的鸟瞰图II。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2026-08-26 DOI: 10.1177/19322968261467418

Mika Hatada, Junko Okuda-Shimazaki, Koji Sode

{"title":"Glucose Oxidoreductases for Glucose Monitoring: A Bird's Eye View of Glucose-Sensing Enzymes II.","authors":"Mika Hatada, Junko Okuda-Shimazaki, Koji Sode","doi":"10.1177/19322968261467418","DOIUrl":"10.1177/19322968261467418","url":null,"abstract":"Biosensors, utilizing glucose oxidoreductases as biological recognition elements (BREs), underpin current blood glucose monitoring (BGM) and continuous glucose monitoring (CGM) technologies. Glucose oxidase remains the gold standard due to its high selectivity and stability, yet its oxygen dependency limits it to first- and second-generation sensing. Fungal flavin adenine dinucletotide (FAD)-dependent glucose dehydrogenase (GDH) has emerged as the standard for mediator-based second-generation sensors due to its oxygen insensitivity, though it requires further engineering to match the stability and selectivity for CGM applications. Recent research increasingly prioritizes third-generation sensors capable of direct electron transfer (DET). Bacterial FADGDHs are premier candidates, possessing intrinsic DET capabilities via dedicated covalently bound heme subunits, while cellobiose dehydrogenase represents a rising star utilizing non-covalently bound heme b as a built-in mediator. Both require extensive protein engineering to overcome inherent limitations in substrate specificity and catalytic efficiency toward glucose. This review introduces the protein and enzyme sciences of glucose oxidoreductases, which have been and expected to be applied to blood, interstitial fluid, and other biological fluids. It reviews their reported and expected sensing modalities and engineering strategies, including rational design and chimera construction, to enhance enzyme robustness, selectivity, and the availability of electron acceptors, including DET ability. It also introduces perspectives on future engineering approaches to create ideal glucose-sensing oxidoreductases. This review article is an updated version of \"Review of Glucose Oxidases and Glucose Dehydrogenases: A Bird's Eye View of Glucose Sensing Enzymes,\" which was published in 2011 in the Journal of Diabetes Science and Technology (JDST) (https://doi.org/10.1177/193229681100500507).","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1543-1556"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13518614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148828748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Addressing the Diabetes Tsunami Requires Expanded Access to Diabetes Technologies. 应对糖尿病海啸需要扩大获得糖尿病技术的途径。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-04-10 DOI: 10.1177/19322968251332956

Davida F Kruger, Christopher G Parkin, Irl B Hirsch, Grazia Aleppo, Janet B McGill, Rodolfo J Galindo, Carol J Levy, Guillermo E Umpierrez, George Grunberger, Richard M Bergenstal

引用次数: 0

Accuracy of Factory-Calibrated Continuous Glucose Monitors in Critically Ill Patients Receiving Intravenous Insulin: A Prospective Clinical Trial of Two Leading Systems. 在接受静脉注射胰岛素的危重患者中，工厂校准的连续血糖监测仪的准确性：两种领先系统的前瞻性临床试验。

IF 4.9

Journal of Diabetes Science and Technology Pub Date : 2026-09-01 Epub Date: 2025-05-08 DOI: 10.1177/19322968251338865

Gautam Ramesh, Emily Kobayashi, Navyaa Sharma, Amit R Majithia, Kristen Kulasa, Schafer C Boeder

{"title":"Accuracy of Factory-Calibrated Continuous Glucose Monitors in Critically Ill Patients Receiving Intravenous Insulin: A Prospective Clinical Trial of Two Leading Systems.","authors":"Gautam Ramesh, Emily Kobayashi, Navyaa Sharma, Amit R Majithia, Kristen Kulasa, Schafer C Boeder","doi":"10.1177/19322968251338865","DOIUrl":"10.1177/19322968251338865","url":null,"abstract":"Background: Continuous glucose monitors (CGMs) are increasingly being used to guide glucose management in the hospital. However, uncertainty regarding their accuracy in this setting remains.Methods: We conducted a nonrandomized, open-label, clinically blinded prospective trial of the Dexcom G6 Pro (G6P) and FreeStyle Libre Pro (FLP) in the inpatient setting among critically ill hospitalized patients (n = 40) requiring continuous intravenous insulin infusion. In parallel with CGM data, reference serum (Lab) glucose and point-of-care (POC) glucose values were obtained. On completion of the study, CGM and reference values were analyzed to assess CGM accuracy.Results: A total of 1015 matched G6P-Lab pairs had a mean absolute relative difference (MARD) of 22.7%, 2369 G6P-POC pairs had an MARD of 22.9%, 1006 matched FLP-Lab pairs had an MARD of 25.2%, and 2353 FLP-POC pairs had an MARD of 27.0%. Both CGM systems demonstrated considerable inter-patient variability in sensor accuracy and tended to underestimate glucose in comparison with the reference values. Rarely were low reference values overestimated by either sensor.Conclusions: Factory-calibrated continuous glucose monitors may require accuracy validation and per-patient calibration for inpatient use in critically ill patients.","PeriodicalId":15475,"journal":{"name":"Journal of Diabetes Science and Technology","volume":" ","pages":"1585-1594"},"PeriodicalIF":4.9,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144007741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0